IPM Take
Cardiovascular prevention has spent decades talking about cholesterol, blood pressure, smoking, diet and exercise. Sleep was treated as softer, vaguer and less clinical. That era is over. Sleep duration, sleep quality, sleep regularity and sleep disorders are now tied to hypertension, metabolic disease and cardiovascular outcomes. But the policy response is still weak. If primary care is expected to screen and counsel patients on sleep, health systems need time, tools, referral pathways and reimbursement. Otherwise, “sleep health” becomes another unpaid prevention task handed to already overloaded clinicians.
Executive Summary
A Patient Care Online interview linked to SLEEP 2026 highlights the role of sleep hygiene counselling in cardiovascular risk reduction in primary care. Virend Somers, Professor of Cardiovascular Medicine at Mayo Clinic, discussed how primary care physicians can address sleep in routine visits, including sleep regularity, sleep duration variability and basic counselling as practical starting points.
The topic reflects a broader shift. The American Heart Association added sleep duration as the eighth component of Life’s Essential 8 in 2022, alongside diet, physical activity, nicotine exposure, weight, cholesterol, blood glucose and blood pressure. AHA guidance states that most adults need 7-9 hours of sleep per night.
The cardiovascular rationale is clear. Insufficient sleep is associated with obesity, diabetes, hypertension, heart disease and stroke. Sleep disorders, including obstructive sleep apnea and insomnia, can affect blood pressure control, metabolic health and cardiovascular risk. Yet sleep assessment is still inconsistent in routine primary care, and many clinicians lack practical tools, time and referral options.
The policy question is not whether sleep matters. It is whether health systems are willing to make sleep part of cardiovascular prevention infrastructure rather than leaving it as a brief lifestyle comment at the end of a rushed appointment.
Why it matters
- Policymakers and public authorities: Sleep health should be included in cardiovascular and noncommunicable disease prevention strategies, with attention to shift work, housing, digital exposure, mental health and social inequality.
- Payers: Reimbursement models should support sleep screening, counselling, home sleep testing where appropriate, insomnia interventions and referral pathways, not only downstream treatment of hypertension and cardiovascular disease.
- Primary care clinicians: Sleep can become a practical risk conversation in routine visits, but clinicians need short validated tools, escalation criteria and clear pathways for suspected sleep apnea, insomnia and other disorders.
- Cardiologists and sleep specialists: Patients with resistant hypertension, atrial fibrillation, heart failure or cardiometabolic risk may need sleep assessment as part of risk management, not as an optional referral after everything else fails.
- Patients and advocates: Sleep advice must avoid blame. Many patients face unsafe housing, night shifts, caregiving, stress, pain, menopause symptoms, mental health problems or untreated sleep disorders that cannot be fixed by generic “sleep hygiene” tips alone.
Sleep has quietly become a cardiovascular risk factor. Policy has not caught up.
At SLEEP 2026 in Baltimore, Virend Somers, Professor of Cardiovascular Medicine at Mayo Clinic, discussed how primary care physicians can bring sleep into routine cardiovascular risk management. The message was practical: ask about sleep regularity, sleep duration, variability and basic sleep hygiene. Start somewhere.
That sounds simple. It is not.
Primary care is already drowning in prevention tasks: blood pressure, diabetes, cholesterol, obesity, smoking, alcohol, mental health, vaccines, cancer screening, medicines, referrals and social needs. Adding sleep to the list only works if health systems treat it as a real component of cardiovascular care, not another box clinicians are expected to tick without time or reimbursement.
The science is strong enough to force the issue. In 2022, the American Heart Association updated Life’s Simple 7 to Life’s Essential 8 by adding sleep duration. That was not cosmetic. It was a recognition that sleep belongs alongside diet, physical activity, nicotine exposure, body weight, cholesterol, blood glucose and blood pressure in defining cardiovascular health.
CDC data reinforce the scale of the problem. In 2020, 35% of US adults reported insufficient sleep duration, defined as fewer than seven hours in a 24-hour period. CDC links insufficient sleep with higher risk of chronic conditions including obesity, diabetes, hypertension, heart disease and stroke.
Sleep is not one problem. That is why policy has been slow.
Obstructive sleep apnea has the most established cardiovascular evidence base and is closely linked to hypertension and cardiometabolic risk. But insomnia, restless legs syndrome, narcolepsy, circadian disruption, shift work and irregular sleep patterns also matter. They require different clinical responses. Sleep hygiene advice may help some patients, but it will not diagnose obstructive sleep apnea or treat chronic insomnia by itself.
That distinction is politically important.
If health systems reduce sleep health to advice about screens, caffeine and bedtime routines, they will miss the patients who need structured assessment, cognitive behavioural therapy for insomnia, home sleep testing, specialist referral or treatment for sleep apnea. “Sleep better” is not a care pathway.
The cardiovascular implications are especially clear in hypertension. A patient with high blood pressure and untreated sleep apnea may not achieve adequate control through medicines alone. If sleep is not assessed, clinicians may intensify pharmacological treatment without addressing a driver of poor control. That is not personalised prevention. It is fragmented care.
The global policy angle is bigger than the clinic. Sleep is shaped by work, poverty, housing, safety, noise, stress and digital environments. Night-shift workers, caregivers, people in insecure housing, low-income communities, women navigating menopause symptoms, and people with mental health conditions may face higher barriers to healthy sleep. Cardiovascular prevention cannot pretend sleep is purely an individual choice.
This is where health equity becomes unavoidable.
A wearable device can tell a wealthy patient they slept badly. It does not give a night-shift worker control over their schedule. It does not make housing quieter. It does not shorten a two-hour commute. It does not provide childcare, treat chronic pain or pay for sleep apnea testing.
Digital sleep tools may help, but they are not policy.
The risk is that sleep becomes another consumerised prevention market: apps, trackers, mattresses and wellness advice for people already engaged with health. Meanwhile, patients with the highest cardiometabolic risk may remain undiagnosed, untreated and told to improve habits they have little power to change.
A serious cardiovascular sleep strategy would look different.
Primary care should have short screening questions for sleep duration, sleep regularity, snoring, witnessed apneas, daytime sleepiness, insomnia symptoms and shift work. Electronic health records should make sleep visible alongside blood pressure, BMI, smoking status and diabetes risk. Referral pathways should distinguish who needs counselling, who needs behavioural therapy, who needs sleep testing and who needs specialist care.
Payers should stop treating sleep as optional. Screening and counselling take time. Cognitive behavioural therapy for insomnia requires trained providers. Sleep apnea testing and treatment require coverage. Follow-up matters. Without reimbursement, sleep health remains a clinical recommendation without a delivery model.
Cardiology also needs to own part of this agenda. Patients with resistant hypertension, atrial fibrillation, heart failure, obesity, type 2 diabetes or recurrent cardiovascular events should not have sleep risk treated as a side issue. It should be part of cardiometabolic risk assessment.
This does not mean every patient needs a sleep study. It means every cardiovascular prevention pathway should know when sleep risk is relevant and what happens next.
The policy gap is visible in the language. Diet and exercise are treated as prevention. Blood pressure and cholesterol are treated as clinical risk factors. Sleep still too often sits in the wellness category. That framing is outdated.
Sleep is biology. Sleep is behaviour. Sleep is environment. Sleep is labour policy. Sleep is mental health. Sleep is cardiovascular prevention.
The next step is implementation.
SLEEP 2026’s message to primary care is useful: start asking. But asking is only the first step. If a clinician asks and the system cannot respond, patients are left with awareness but no support.
Health systems cannot keep adding modifiable risk factors to prevention frameworks without funding the machinery to modify them.
The heart does not stop needing prevention at night.
